Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B
Authors:
- 29 August 2010
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 32 (9) , 1059-1068
Abstract
Aliment Pharmacol Ther 2010; 32: 1059–1068Summary: Background The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain.Aim To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma, cirrhotic complications and liver‐related mortality) in chronic hepatitis B patients.Methods Randomized controlled trials, case–control studies and cohort studies were retrieved from electronic databases and conference abstracts. Relative risks (RRs) of different hepatic complications among patients treated by IFN‐α vs. no treatment or placebo were studied.Results Eleven studies were identified totalling 975 patients treated by IFN‐α vs. 1147 untreated controls for analysis. Patients were treated by IFN‐α for 1–24 months with a post‐treatment follow‐up of 1–13 years. Treatment by IFN‐α reduced the risk of overall hepatic events (RR 0.55, 95% confident interval or CI 0.43–0.70, P < 0.001) and cirrhotic complications (RR 0.46, 95% CI 0.32–0.67, P < 0.001) by 45% and 54% respectively. Patients who responded to IFN‐α had more profound reduction in overall hepatic events (RR 0.20, 95% CI 0.05–0.87, P = 0.03) and cirrhotic complications (RR 0.19, 95% CI 0.09–0.38, P < 0.001) vs. the untreated controls.Conclusion Interferon‐alfa treatment reduces the risk of hepatic events particularly among responders to treatment.Keywords
This publication has 42 references indexed in Scilit:
- Predictors of Treatment Response in Chronic Hepatitis BDrugs, 2009
- Hepatocellular Carcinoma and Hepatitis B VirusSeminars in Liver Disease, 2006
- Antifibrogenic Effect of IFN- α 2b on Hepatic Stellate Cell Activation by Human HepatocytesJournal of Interferon & Cytokine Research, 2006
- Peg‐interferon improves liver histology in patients with HBeAg‐positive chronic hepatitis B: no additional benefit of combination with lamivudineLiver International, 2006
- Rat liver fibrosis regresses better with pegylated interferon α2b and ursodeoxycholic acid treatments than spontaneous recoveryLiver International, 2006
- Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferonAlimentary Pharmacology & Therapeutics, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis BJournal of Hepatology, 2001
- Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosisJournal of Hepatology, 1996
- Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trialJournal of Hepatology, 1994